Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LSA-3-rec
- Development stage
- Phase 2
- Lead developer
- Institut Pasteur
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
LSA-3-rec is a recombinant protein subunit vaccine candidate developed by the Biomedical Parasitology Unit at Institut Pasteur (Paris, France). It is designed to prevent malaria caused by *Plasmodium falciparum* by targeting the Liver Stage Antigen-3 (PfLSA-3), a highly conserved pre-erythrocytic antigen expressed during the liver stage of the parasite's life cycle. By inducing immune responses against the liver stage, the vaccine aims to prevent the parasite from progressing to the symptomatic blood stage of infection. LSA-3-rec has been evaluated in Phase I/IIa clinical trials in healthy adult volunteers to assess its safety, immunogenicity, and protective efficacy against controlled human malaria infection (CHMI) using sporozoite challenge.
- Other names
- PfLSA-3 vaccinePfLSA3 vaccinePfLSA 3 vaccinePlasmodium falciparum Liver Stage Antigen-3 recombinant vaccine
02
Targets
TCR-LSA3 (Human T-cell receptor recognizing Liver Stage Antigen 3 (LSA-3))LSA-3 (Plasmodium falciparum liver-stage antigen 3)PfLSA-3 (Plasmodium falciparum liver-stage antigen 3 (LSA-3))
Beyond the preview
Go deeper on LSA-3-rec.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LSA-3-rec.